Phase I Multiple Ascending Dose study for AZD 7268 in Healthy Volunteers
Study identifier:D1151C00003
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A Phase I, Single-center, Double-blind, Randomized, Placebo-controlled Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD7268 When Given in Multiple Ascending Oral Doses in Healthy Subjects
Medical condition
Healthy
Phase
Phase 1
Healthy volunteers
Yes
Study drug
AZD7268, Placebo
Sex
All
Actual Enrollment
40
Study type
Interventional
Age
18 Years - 45 Years
Date
Study Start Date: 01 Apr 2009
Primary Completion Date: -
Study Completion Date: 01 Oct 2009
Study design
Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Double Blind
Primary Purpose: Other
Verification:
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: AZD7268 | Drug: AZD7268 Capsule, Oral, QD Drug: AZD7268 Capsule, Oral, BID |
| Placebo Comparator: Placebo | Drug: Placebo Capsule, Oral BID Drug: Placebo Capsule, Oral BID |
Contacts
Investigators
Principal Investigator
Sylvan Hurewitz
AstraZeneca Clinical Pharmacology Unit, US
